A multi-center, randomized, double-blind, active-control, 96 week, phase III trial of the efficacy and safety of clevudine compared with adefovir at weeks 48 and 96 in nucleoside treatment-naive patients with HBeAg positive chronic hepatitis due to hepatitis B virus.

Trial Profile

A multi-center, randomized, double-blind, active-control, 96 week, phase III trial of the efficacy and safety of clevudine compared with adefovir at weeks 48 and 96 in nucleoside treatment-naive patients with HBeAg positive chronic hepatitis due to hepatitis B virus.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Adefovir; Clevudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms QUASH-1
  • Sponsors Pharmasset
  • Most Recent Events

    • 20 Apr 2009 Status changed from recruiting to discontinued, according to Pharmasset media release.
    • 08 Jul 2008 Pharmasset plans to submit the 48-week data to the FDA as the basis for clevudine marketing approval.
    • 31 Dec 2007 Pharmasset expects patient enrolment to be complete within the second half of 2008; reported in fiscal year end 2007 results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top